PATHOSCRIBEAI PRIVATE LIMITED

In their own words

At PathoscribeAI, we are transforming the landscape of pharmaceutical research and development through our proprietary AI agent, engineered to understand and decode the complexity of biology and medicine. Established in 2025 by a team of AI experts and scientists, our mission is to accelerate therapeutic discovery by reimagining how medicines are found, validated, and repurposed. Our intelligent platform seamlessly integrates advanced machine learning, computational biology, and systems pharmacology to analyze vast biological datasets and uncover insights that lead to breakthrough therapies. The PathoscribeAI agent is designed to power every stage of modern drug development—from de novo drug discovery using AI-driven molecular design pipelines to drug repurposing through in-silico high-throughput screening. It also enables intelligent target identification, biomarker prediction, and large-scale analysis of clinical and molecular data, helping researchers move from hypothesis to validation faster than ever before. We collaborate with pharmaceutical partners to streamline their R&D pipelines, reducing time-to-market, minimizing costs, and unlocking hidden value in molecular and clinical data assets. By combining deep scientific understanding with powerful computational tools, we aim to eliminate inefficiencies in traditional drug discovery and accelerate the journey from data to drug. Our vision is to make AI-driven pharmacology the new benchmark for innovation—one that not only speeds up discovery but also improves patient outcomes and enhances the global healthcare ecosystem. At PathoscribeAI, we believe that the future of medicine lies at the intersection of intelligent computation and biological insight.

Written by the company on its public Startup India profile. Not verified by us.